Medical Cannabis / Psychedelics

[Dobbin]

Full disclosure. I am the CEO of a Medical Cannabis company. I think that the industry is currently viewed in a questionable light given the steep price declines in publicly traded Cannabis companies in North America and the UK. We have seen a lot of frothy investor sentiment over the past few years particularly in the UK in early 2021 which has of course resulted in companies with questionable business models being funded. Which in turn has resulted in most early investors losing money.
I believe that correctly positioned companies offer an excellent risk capital opportunity for UK investors.
4C LABS will be launching a new product line in the UK in May which will undercut the current legal and illicit markets by up to 50%, with better quality products and backed by our customer service guarantee.
I am available anytime to talk UK / EU macro cannabis industry, investment strategies and my personal take on where the industry is headed and what to watch out for as an investor. I can give you the straight goods on companies with Clinical Trial Models, Production Models, Clinic Models as well as realistic projections of patient growth, patient spend and highlight the current regulatory bottlenecks in the UK market.
An example of above. A company growing in the UK or EU can't compete against companies growing in other jurisdictions and exporting to the UK / EU. Why? Electricity costs, labour costs and new build infrastructure costs.

Happy to discuss as an in forum topic or PM.
G

[LabrandoT]

Thanks for sharing your perspective as the CEO of a Medical Cannabis company. It's true that the cannabis industry has seen some ups and downs, and investor sentiment can be quite unpredictable.

[Annefnd]

Your insights on the current state of the cannabis industry are spot on. The rapid growth and subsequent market corrections have indeed left many investors wary. However, as you mentioned, there is still significant potential for well-positioned companies to thrive, especially those that can offer competitive pricing and superior quality products.

The upcoming launch of 4C LABS' new product line in the UK sounds like a strategic move, particularly with the promise to undercut both legal and illicit markets by up to 50%. This kind of competitive pricing, combined with a focus on quality and customer service, could indeed attract a substantial market share.

Your willingness to discuss investment strategies and provide insights into various business models and regulatory challenges in the UK/EU market is valuable. Investors can greatly benefit from understanding the nuances of clinical trial models, production models, and clinic models, as well as realistic projections of patient growth and spend.

Highlighting the advantages and disadvantages of growing within the UK/EU compared to importing from other jurisdictions is crucial. The cost differences in electricity, labor, and infrastructure can significantly impact profitability and competitiveness.

It would be great to dive deeper into these topics in a forum discussion or through private messages. Sharing your expertise could help demystify the industry for potential investors and provide a clearer picture of the opportunities and challenges ahead.